The Medical Genetics & Genomics Revenue Reality
Medical Genetics & Genomics is documentation-sensitive, policy-sensitive, and highly vulnerable to payer-specific testing rules. Revenue leakage builds through incomplete phenotype documentation, medical-necessity mismatch, and incorrect gene-specific or panel code selection.
- Incomplete phenotype and family-history documentation
- Medical-necessity mismatch between diagnosis and test
- Gene-specific, panel, PLA, and unlisted-code errors
- Prior authorization and payer policy mismatch
- Coverage variation across commercial and Medicare pathways
- Delayed reimbursement on high-complexity molecular claims
- Rebilling friction on denied or individually reviewed tests
- Aging AR concentration in genetics consult claims
Molecular Coding & Claim Precision (CCP)
- Gene-specific and panel coding integrity checks
- PLA and unlisted-code governance
- Diagnosis-to-test medical-necessity validation
- Documentation alignment for phenotype and history
- Claim-level review for molecular pathology accuracy
- Order, report, and coding consistency controls
Target Outcome: Reduced molecular billing errors and fewer denials.
Front-End Eligibility, Authorization & Coverage Controls (FIO + EAE)
- Real-time eligibility verification
- Prior authorization tracking and renewal controls
- Payer-policy validation for genetic testing
- Medical-necessity documentation checkpoints
- Coverage pathway review for molecular diagnostics
- Ordering and referral workflow validation
Target Outcome: Fewer eligibility-related rejections and cleaner claims.
High-Value AR Recovery & Denial Resolution (AAF)
- Structured follow-up on denied molecular claims
- Payer-specific appeal workflows for medical necessity
- Follow-up prioritization for individually reviewed claims
- AR > 90 monitoring by payer and test class
- Underpayment review on reimbursed molecular services
Target Outcome: Faster recovery of delayed reimbursements for complex claims.
Test Utilization & Reimbursement Pattern Intelligence (PRL)
- Denial trends by payer and molecular category
- Reimbursement variance monitoring across test types
- Prior authorization failure clustering
- High-value AR aging concentration by payer mix
- Unlisted-code and reviewed claim visibility
Target Outcome: Clear visibility into genetic revenue leakage.
Measurable Performance Targets
- 8–18% increase in net collections
- 15–30% reduction in denial rates
- 25–40% reduction in AR > 90
- 95–98% first-pass claim acceptance
- Improved consistency for molecular diagnostics and genomics
Compliance & Infrastructure
- HIPAA-compliant workflows with BAA signed prior to PHI exchange
- Integration with major EHR platforms including Epic, Cerner, Athenahealth, NextGen, eClinicalWorks and others
- Cybersecurity oversight via Redfort Technologies
- U.S.-based nationwide operations
Are Your Genetics Consults, Molecular Claims, and Genomic Testing Workflows Being Reimbursed at Full Contracted Rates?
Schedule a specialized Medical Genetics & Genomics Revenue Audit and identify how coding accuracy, documentation gaps, and denial patterns are affecting your claims, AR performance, and net collections.
Schedule a FREE Audit Now